<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F0A3F403-8578-47AC-A520-9E6B1EDFC18F"><gtr:id>F0A3F403-8578-47AC-A520-9E6B1EDFC18F</gtr:id><gtr:firstName>Bill</gtr:firstName><gtr:surname>Deakin</gtr:surname><gtr:orcidId>0000-0002-2750-962X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_11003"><gtr:id>E7CD4AA2-3740-4E3A-836C-40C4F8E038FA</gtr:id><gtr:title>The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_11003</gtr:grantReference><gtr:abstractText>One of the major disabilities affecting the quality of life of people with schizophrenia is the development of a set of so-called negative symptoms comprising social withdrawal, self-neglect, loss of motivation and mild impairment of intelligence. Standard drug treatments are effective in reducing psychotic symptoms such as paranoid delusions and hearing voices, but they have little impact on negative symptoms. Two formal clinical trials suggest that a standard antibiotic and anti-inflammatory drug called minocycline commonly used in acne and other infections, reduces negative symptoms. In both studies patients with stable symptoms took either minocycline or exactly matching dummy tablets (placebo) in addition to their routine treatment for 6 or 12 months. Negative symptoms improved twice as much in those taking additional minocycline than in those taking the dummy tablets. It also lessened the weight gain that standard treatments usually cause. Other studies suggest that minocycline may also improve positive symptoms in acute episodes of illness. The aim of this proposal is to investigate whether minocycline is especially effective given early in the course of illness and to understand how it works. The proposal is to compare minocycline with placebo capsules added to each person?s treatment within 3 years of starting it. We will follow the effects on positive and negative symptoms over 12 months. Minocycline might work by protecting brain cells from damage possibly caused by inflammation. Brain imaging will tell us whether subtle changes in the grey matter of the brain in schizophrenia are lessened by minocycline over 12 months and whether this accounts for reduced negative symptoms. Measuring chemicals (cytokines) in the blood will tell us whether minocycline is working by blocking inflammation in the brain. Another possibility is simply that minocycline helps negative symptoms by helping brain cells work better and this can also be studied using modern brain imaging methods and by determining whether improvements are lost when the drug is stopped. This multicentre UK-wide study will be carried out by a group of experienced researchers in early psychosis that have worked together over several years to set up and test a secure UK research network for people in their first episode of psychosis. It is called PsyGrid (www.psygrid.org) and was funded by the Medical Research Council and the Department of Health. Clinical assessments from 960 patients were gathered in two years in 8 centres of the Mental Health Research Network (MHRN) in England. We have also shown that we can reliably combine brain imaging results using different brain scanners in different centres (www.neuropsygrid.org).</gtr:abstractText><gtr:technicalSummary>AIMS: to use recently developed PsyGrid infrastructure for UK-wide clinical and imaging research in first episode psychosis to: i) determine whether negative symptoms can be lessened or prevented by minocycline treatment initiated early in the course of schizophrenia and ii) collect biomarker data to test hypotheses about how minocycline improves negative symptoms. PRIMARY EFFICACY PREDICTION AND MECHANISTIC HYPOTHESES: 1) Minocycline minimises later negative symptoms when administered during the acute phase of early psychosis 2) Minocycline reduces or prevents the negative symptoms of schizophrenia by: a) reducing the loss of grey matter associated with early psychosis. b) interfering with inflammatory cytokine production. c) an action on glutamate systems to improve negative symptoms and cognitive function. DESIGN. Multicentre, one year, double-blind randomised placebo-controlled trial of minocycline versus placebo, added to standard antipsychotic drug (APD) treatment, for patients in an early episode of schizophrenia-related psychosis. INTERVENTION. Minocycline or matching placebo 300mg daily for 12 months. OUTCOMES. The primary clinical outcome is negative symdrome subscale score on the Positive and Negative Syndrome Scale (PANSS). The mechanistic biomarker variables are: 1) change in medial prefrontal grey matter volume over 12 months, 2) circulating cytokine concentrations and 3) working memory performance and brain activation. These measures will be related to changes in PANSS negative symptoms at 2, and 12 months and to quality of life assessments. POPULATION AND SAMPLE SIZE. 170 patients with early psychosis recruited over 22 months from 6 established PsyGrid centres. STATISTICAL ANALYSIS. Group differences in outcomes and putative mediators will be evaluated using random effects models for longitudinal data (allowing for treatment centre and other baseline covariates). Tests of the mechanistic hypotheses (i.e. mediation), and their sensitivity of the results to possible hidden confounding, will use instrumental variable methods from PI Dunn?s MRC Methodology Research Programme projects; see Emsley R, Dunn G &amp;amp; White I (2009) modelling mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Statistical Methods in Medical Research published online on 16/07/09. EXPERTISE. The investigators are experienced in the recruitment of early psychosis patients and the confidential collection of clinical assessments and brain imaging through their involvement in PsyGrid and NeuroPsyGrid.</gtr:technicalSummary><gtr:fund><gtr:end>2016-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-07-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1613546</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir Peter Mansfield Magnetic Resonance Centre</gtr:department><gtr:description>MRC Spring study</gtr:description><gtr:id>66834031-E657-4E73-9D2A-6DD979B10B64</gtr:id><gtr:impact>Just starting</gtr:impact><gtr:outcomeId>548ad7bab12940.31054402-1</gtr:outcomeId><gtr:partnerContribution>3 centre collaboration to recruit patients with early and established psychosis for biomarkers of glutamate, GABA neurochemistry and function in early psychosis</gtr:partnerContribution><gtr:piContribution>Cubric: magneto ecncepahalography (MEG) &amp;amp; magnetic resonance spectroscopy (MRS)
Nottingham: MEG and c13 MRS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Psychiatry, Psychology &amp; Neuroscience</gtr:department><gtr:description>BeneMin</gtr:description><gtr:id>8D36D5A8-DFBA-49D6-B330-0276BFEDEA96</gtr:id><gtr:impact>in pregress</gtr:impact><gtr:outcomeId>548ae019c83c37.54084488-2</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>We lead the BeneMin clinic trial of minocycline in early psychosis. EME/NIHR grant</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Queen Elizabeth Medical Centre, Birmingham</gtr:department><gtr:description>BeneMin</gtr:description><gtr:id>2C01D828-1F59-4451-872C-A9C124016042</gtr:id><gtr:impact>in pregress</gtr:impact><gtr:outcomeId>548ae019c83c37.54084488-1</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>We lead the BeneMin clinic trial of minocycline in early psychosis. EME/NIHR grant</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Psychiatry</gtr:department><gtr:description>BeneMin</gtr:description><gtr:id>4CC85792-535D-4028-A07F-41DCB92A6D10</gtr:id><gtr:impact>in pregress</gtr:impact><gtr:outcomeId>548ae019c83c37.54084488-4</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>We lead the BeneMin clinic trial of minocycline in early psychosis. EME/NIHR grant</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Neuroscience</gtr:department><gtr:description>BeneMin</gtr:description><gtr:id>8B0338FA-1578-44EA-832C-D673DBC29E25</gtr:id><gtr:impact>in pregress</gtr:impact><gtr:outcomeId>548ae019c83c37.54084488-3</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>We lead the BeneMin clinic trial of minocycline in early psychosis. EME/NIHR grant</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>BeneMin</gtr:description><gtr:id>0D993E72-17FF-4919-8587-5ABEA8A613AD</gtr:id><gtr:impact>in pregress</gtr:impact><gtr:outcomeId>548ae019c83c37.54084488-5</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>We lead the BeneMin clinic trial of minocycline in early psychosis. EME/NIHR grant</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Brain Research Imaging Centre (CUBRIC)</gtr:department><gtr:description>MRC Spring study</gtr:description><gtr:id>520F00F9-4546-4022-AB20-E97351514D86</gtr:id><gtr:impact>Just starting</gtr:impact><gtr:outcomeId>548ad7bab12940.31054402-2</gtr:outcomeId><gtr:partnerContribution>3 centre collaboration to recruit patients with early and established psychosis for biomarkers of glutamate, GABA neurochemistry and function in early psychosis</gtr:partnerContribution><gtr:piContribution>Cubric: magneto ecncepahalography (MEG) &amp;amp; magnetic resonance spectroscopy (MRS)
Nottingham: MEG and c13 MRS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Article in Independent newspaper</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>03419015-1287-4B63-9688-CB6E71A2049C</gtr:id><gtr:impact>Cheap Acne Drug Helps Mental Illness
Front Page news 2/3/2012


Many enquiries from patients and carers about joining the BeneMin study.</gtr:impact><gtr:outcomeId>W6jkpy2y3SW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2C015543-D66F-440F-808A-6D2D786A38EF</gtr:id><gtr:impact>hosted student for 2 weeks.

university course applied for in related area
Got into Nottingham Medical school</gtr:impact><gtr:outcomeId>51EDA438F64</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European College of Neuropsychopharmacology  Talk of the Month</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ED0D2499-436F-44B8-BA3D-147C9DE0A13E</gtr:id><gtr:impact>Neuroinflammation and the possibility of preventing schizophrenia 



313 hits on youtube. Unknown number on ECNP website</gtr:impact><gtr:outcomeId>DGzLt46Ywyk</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=WzM8IG-avpM</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>&quot;Reassembling the Self&quot; Psychosis, Schizophrenia and Art. I month exhibition + Co-organiser and Opening  speaker at 1-day symposium for 150 service users and relatives. Waterside Gallery</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>95B1D2CA-5630-43EF-93BF-2A4C506C7797</gtr:id><gtr:impact>Co-organiser and Opening speaker at 1-day symposium for 150 service users and relatives. Waterside Gallery</gtr:impact><gtr:outcomeId>58c47ad22984b6.55806309</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>https://www.watersideartscentre.co.uk/whats-on/?category=reassembling-the-self</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Clinical trials of novel treatments for schizophrenia</gtr:description><gtr:fundingOrg>Stanley Medical Research Institute (SMRI)</gtr:fundingOrg><gtr:id>40313A13-3E1F-48F1-B13D-51CD63BA381E</gtr:id><gtr:outcomeId>58c46bfaa72526.53263488</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Clinical trials of novel treatments for schizophrenia</gtr:description><gtr:fundingOrg>Stanley Medical Research Institute (SMRI)</gtr:fundingOrg><gtr:id>358A5365-5C99-4AE3-AAA3-27CAB39B5E03</gtr:id><gtr:outcomeId>58c46cdbd0fde7.76104797</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3422098</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC challenge scheme</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K020803/1</gtr:fundingRef><gtr:id>A4A81C7C-1227-4191-BD14-9AC961CD0D01</gtr:id><gtr:outcomeId>mJnX5pWgdvZ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3920095</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stratified Medicine</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L011794/1</gtr:fundingRef><gtr:id>C5CDA3AA-CA6A-42CC-84A5-C8AAB2F54971</gtr:id><gtr:outcomeId>XbZq7EJLX77</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>455071</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sunovion commercial</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>P1vital Consortium</gtr:fundingOrg><gtr:id>CA4A26A6-0EE0-4FCC-9626-F5B825A3347C</gtr:id><gtr:outcomeId>5464af7c926886.25700666</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Clinical trial of minocycline added to treatment as usual for early schizophrenia primary efficacy end point - improvement of negative symptoms over 12 months; primary mechanistic end point - prevention of grey matter loss using imaging in early psychosis. 207 patients recruited within 24 months to target and on time</gtr:description><gtr:id>6E50B7C0-43D4-4729-A287-72985F0131CF</gtr:id><gtr:impact>The results are being analysed</gtr:impact><gtr:outcomeId>58c4848fd80946.48476485</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Minocycline</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9ECDC98D-5419-4EF4-8A44-2155442F2FF4</gtr:id><gtr:title>The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49cd05f8afd80aef103ba5359746ea7e"><gtr:id>49cd05f8afd80aef103ba5359746ea7e</gtr:id><gtr:otherNames>Lisiecka DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58c42125727621.04039715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D20ECCB-C876-4B0D-AA1B-7CC180B870E5</gtr:id><gtr:title>Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/922a2264caa86d76d27b0a3269e8033f"><gtr:id>922a2264caa86d76d27b0a3269e8033f</gtr:id><gtr:otherNames>Chaudhry IB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_15540_20_23782463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0144EFA8-0751-4335-90F8-57307E91774D</gtr:id><gtr:title>A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/922a2264caa86d76d27b0a3269e8033f"><gtr:id>922a2264caa86d76d27b0a3269e8033f</gtr:id><gtr:otherNames>Chaudhry IB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5aa066233a1e51.26171609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0607893-E26A-4E00-B1B9-2860BC9D2F6E</gtr:id><gtr:title>Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Neuropsychiatric disease and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e676e8f03f355d08cc5c54b563ab48e"><gtr:id>5e676e8f03f355d08cc5c54b563ab48e</gtr:id><gtr:otherNames>Husain MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1176-6328</gtr:issn><gtr:outcomeId>58c41aca522a56.19126458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88FF8C82-4365-4E89-A483-313F04FC3B53</gtr:id><gtr:title>Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e676e8f03f355d08cc5c54b563ab48e"><gtr:id>5e676e8f03f355d08cc5c54b563ab48e</gtr:id><gtr:otherNames>Husain MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56e05bd27ddcc7.21857879</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_11003</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>